PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), a biotechnology company in the clinical stage, has announced a partnership with BeiGene , Ltd. (NASDAQ: NASDAQ:BGNE) to initiate a clinical trial for a new cancer treatment.
The study will evaluate the safety and efficacy of Bria-OTS™, BriaCell’s novel immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, specifically targeting advanced, heavily pretreated metastatic breast cancer.
Dr. William V. Williams, President & CEO of BriaCell, expressed enthusiasm about the collaboration, which aims to expand into prostate and other cancers in the future. The Bria-OTS™ platform builds upon the success of Bria-IMT™, which has demonstrated clinical benefits in patients resistant to checkpoint inhibitors (CPIs) and after progression on antibody drug conjugates (ADCs).
According to Dr. Del Priore, BriaCell’s Chief Medical Officer, there is a rationale to predict that the combination of Bria-OTS™ with tislelizumab may provide additional benefits to this particularly refractory patient population. The Phase 1/2 clinical trial will initially assess the safety and efficacy of Bria-OTS™ alone in breast cancer, with plans to later test it in combination with tislelizumab.
Furthermore, BriaCell intends to explore the potential of Bria-OTS™ in treating prostate and other cancers.
This news is based on a press release statement.
InvestingPro Insights
In the wake of BriaCell Therapeutics' announcement of its partnership with BeiGene, Ltd. for a new cancer treatment clinical trial, investors and industry observers are closely monitoring BeiGene's performance metrics and market position. According to InvestingPro data, BeiGene holds a market capitalization of $15.97 billion, reflecting its substantial presence in the biotechnology industry. An impressive gross profit margin of 78.77% over the last twelve months as of Q1 2024 demonstrates the company's ability to maintain profitability at the gross level, which could be indicative of strong underlying business fundamentals despite the company's overall lack of profitability during this period.
One of the InvestingPro Tips highlights BeiGene as a prominent player in the Biotechnology industry, which may bolster investor confidence in the potential for the company's therapies, including the anti-PD-1 antibody, tislelizumab. However, it's worth noting that analysts have recently revised their earnings downwards for the upcoming period, and the stock has experienced a significant decline over the last week, with a one-week price total return of -8.77%. This volatility underscores the importance of careful consideration of both the opportunities and risks inherent in biotech investments.
For investors seeking a deeper dive into BeiGene's financials and market prospects, InvestingPro offers additional insights. There are currently nine more InvestingPro Tips available, which can provide valuable context for evaluating the company's strategic moves, including the recent partnership with BriaCell. To access these insights and enhance your investment strategy, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
As BriaCell and BeiGene embark on this promising clinical trial, the financial health and industry standing of BeiGene will remain crucial factors for stakeholders to watch. With the dynamic landscape of the biotechnology sector, the partnership's outcome could have significant implications for both companies and their respective therapies in the ongoing fight against cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.